Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

Open link

Publication date

September 2018

DOI

10.6084/m9.figshare.7109873.v1

Abstract

Figure S3. FDG PET. FDG PET SUVR change from baseline in the low-dose SC (A) and high-dose IV (B) cohorts. (PDF 65 kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

Open link

Publication date

September 2018

DOI

10.6084/m9.figshare.7109873.v1

Abstract

Figure S3. FDG PET. FDG PET SUVR change from baseline in the low-dose SC (A) and high-dose IV (B) cohorts. (PDF 65 kb

Extracted data

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S1. A) Distribution of FBB-PET and plasma ratios. B) Shapiro-Wilk test for FBB-PET and plasma...

Additional file 4: of Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Milos Ikonomovic (3399359)
Chris Buckley (3399341)
Kerstin Heurling (3399347)
Paul Sherwin (3399338)
Paul Jones (1523707)
Michelle Zanette (3399344)
Chester Mathis (3399368)
William Klunk (3399353)
Aruna Chakrabarty (3399356)
James Ironside (3399371)
Azzam Ismail (3399350)
Colin Smith (6343)
Dietmar Thal (3399362)
Thomas Beach (559420)
Gill Farrar (3399365)
Adrian Smith (2385022)

December 2016

ROC Analysis: Dichotomised pathology vs continuous SUVR. Comparison of 5 histopathological criteria ...

Additional file 3: of 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Richard Tsai (2839040)
Alexandre Bejanin (6286391)
Orit Lesman-Segev (6286394)
Renaud LaJoie (6286397)
Adrienne Visani (6286400)
Viktoriya Bourakova (6286403)
James O’Neil (6286406)
Mustafa Janabi (6286409)
Suzanne Baker (6286412)
Suzee Lee (6286415)
David Perry (358135)
Lynn Bajorek (6286418)
Anna Karydas (531627)
Salvatore Spina (6251273)
Lea Grinberg (3456281)
William Seeley (3456287)
Eliana Ramos (6286421)
Giovanni Coppola (46572)
Maria Gorno-Tempini (6286424)
Bruce Miller (695078)
Howard Rosen (6029381)
William Jagust (518155)
Adam Boxer (801729)
Gil Rabinovici (2839046)

February 2019

Figure S3. 18F-flortaucipir in FTD, NC and AD 18F-flortaucipir SUVR in temporal and precentral gyrus...

Additional file 1: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Supplementary methods and safety summary. PET imaging parameters and summary of safety findings. (PD...

Additional file 7: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S5. CDR-SB. Change from baseline (BL) of CDR-SB score in patients with mild-to-moderate AD (A...

Additional file 6: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S4. CSF Aβ(1–42) crenezumab correlation analysis. Correlation analysis of change in CSF Aβ(1–...

Additional file 3: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S2. vMRI. Analysis of vMRI change from baseline in the hippocampus (A and B), ventricular vol...

Additional file 2: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...

Additional file 5: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Table S1. Summary of ARIA events. Summary of ARIA events in the low-dose SC cohort, high-dose IV coh...

Additional file 11: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S5. Box plots for TP40 and TP42 by FBB-PET global SUVR status in SCD subjects. (JPEG 53 kb

Additional file 8: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S2. Scatter plots for FBB-PET global SUVR and Aβ plasma ratios in SCD subjects. Correlations ...

Additional file 3: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal FDG and PiB-PET uptake in SUVr(/pons and/cerebellar gray matter) units in brothers A an...

Additional file 2: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal FDG and PiB PET scans for brothers A and B, and corresponding uptake values in SUVr(/ce...

Additional file 1: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Table S1. Demographics and clinical characteristics of subjects studied (FACEHBI [29]) for FBB-PET s...

Additional file 9: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S3. Linear regression between FBB-PET and Aβ TP42/40 plasma ratio in APOE ε4 stratification S...

Additional file 3: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S1. A) Distribution of FBB-PET and plasma ratios. B) Shapiro-Wilk test for FBB-PET and plasma...

Additional file 4: of Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Milos Ikonomovic (3399359)
Chris Buckley (3399341)
Kerstin Heurling (3399347)
Paul Sherwin (3399338)
Paul Jones (1523707)
Michelle Zanette (3399344)
Chester Mathis (3399368)
William Klunk (3399353)
Aruna Chakrabarty (3399356)
James Ironside (3399371)
Azzam Ismail (3399350)
Colin Smith (6343)
Dietmar Thal (3399362)
Thomas Beach (559420)
Gill Farrar (3399365)
Adrian Smith (2385022)

December 2016

ROC Analysis: Dichotomised pathology vs continuous SUVR. Comparison of 5 histopathological criteria ...

Additional file 3: of 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Richard Tsai (2839040)
Alexandre Bejanin (6286391)
Orit Lesman-Segev (6286394)
Renaud LaJoie (6286397)
Adrienne Visani (6286400)
Viktoriya Bourakova (6286403)
James O’Neil (6286406)
Mustafa Janabi (6286409)
Suzanne Baker (6286412)
Suzee Lee (6286415)
David Perry (358135)
Lynn Bajorek (6286418)
Anna Karydas (531627)
Salvatore Spina (6251273)
Lea Grinberg (3456281)
William Seeley (3456287)
Eliana Ramos (6286421)
Giovanni Coppola (46572)
Maria Gorno-Tempini (6286424)
Bruce Miller (695078)
Howard Rosen (6029381)
William Jagust (518155)
Adam Boxer (801729)
Gil Rabinovici (2839046)

February 2019

Figure S3. 18F-flortaucipir in FTD, NC and AD 18F-flortaucipir SUVR in temporal and precentral gyrus...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Supplementary methods and safety summary. PET imaging parameters and summary of safety findings. (PD...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S5. CDR-SB. Change from baseline (BL) of CDR-SB score in patients with mild-to-moderate AD (A...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S4. CSF Aβ(1–42) crenezumab correlation analysis. Correlation analysis of change in CSF Aβ(1–...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S2. vMRI. Analysis of vMRI change from baseline in the hippocampus (A and B), ventricular vol...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...

Stephen Salloway (5194271)
Lee Honigberg (201340)
William Cho (3004272)
Michael Ward (146461)
Michel Friesenhahn (5772140)
Flavia Brunstein (5772143)
Angelica Quartino (5772146)
David Clayton (2150)
Deborah Mortensen (4852741)
Tobias Bittner (237241)
Carole Ho (5772149)
Christina Rabe (5772152)
Stephen Schauer (2307406)
Kristin Wildsmith (5772155)
Reina Fuji (1845652)
Shehnaaz Suliman (5772158)
Eric Reiman (3703348)
Kewei Chen (298512)
Robert Paul (22962)

September 2018

Table S1. Summary of ARIA events. Summary of ARIA events in the low-dose SC cohort, high-dose IV coh...

Additional file 11: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S5. Box plots for TP40 and TP42 by FBB-PET global SUVR status in SCD subjects. (JPEG 53 kb

Additional file 8: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S2. Scatter plots for FBB-PET global SUVR and Aβ plasma ratios in SCD subjects. Correlations ...

Additional file 3: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal FDG and PiB-PET uptake in SUVr(/pons and/cerebellar gray matter) units in brothers A an...

Additional file 2: of Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

Steinunn Thordardottir (5205731)
Elena Rodriguez-Vieitez (5205734)
Ove Almkvist (3463091)
Daniel Ferreira (4515394)
Laure Saint-Aubert (3463088)
Anne Kinhult-Ståhlbom (5205737)
Håkan Thonberg (6730)
Michael Schöll (4742400)
Eric Westman (24165)
Anders Wall (3115698)
Maria Eriksdotter (693854)
Henrik Zetterberg (144718)
Kaj Blennow (58615)
Agneta Nordberg (234998)
Caroline Graff (281203)

May 2018

Longitudinal FDG and PiB PET scans for brothers A and B, and corresponding uptake values in SUVr(/ce...

Additional file 1: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Table S1. Demographics and clinical characteristics of subjects studied (FACEHBI [29]) for FBB-PET s...

Additional file 9: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S3. Linear regression between FBB-PET and Aβ TP42/40 plasma ratio in APOE ε4 stratification S...

Additional file 3: of Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

Itziar de Rojas (5906405)
J. Romero (2449033)
O. Rodríguez-Gomez (6032381)
P. Pesini (6032384)
A. Sanabria (6032387)
A. Pérez-Cordon (6032390)
C. Abdelnour (6032393)
I. Hernández (6032396)
M. Rosende-Roca (6032399)
A. Mauleón (6032402)
L. Vargas (3323727)
M. Alegret (6032405)
A. Espinosa (2100802)
G. Ortega (6032408)
S. Gil (6032411)
M. Guitart (6032414)
A. Gailhajanet (6032417)
M. Santos-Santos (6032420)
Sonia Moreno-Grau (5906360)
O. Sotolongo-Grau (6032423)
S. Ruiz (6032426)
L. Montrreal (6032429)
E. Martín (2473969)
E. Pelejà (6032432)
F. Lomeña (6032435)
F. Campos (6032438)
A. Vivas (6032441)
M. Gómez-Chiari (6032444)
M. Tejero (3484898)
J. Giménez (6032447)
V. Pérez-Grijalba (6032450)
G. Marquié (6032453)
G. Monté-Rubio (6032456)
S. Valero (6032459)
A. Orellana (6032465)
L. Tárraga (6032480)
M. Sarasa (6032483)
A. Ruiz (1524154)
M. Boada (6032486)

November 2018

Figure S1. A) Distribution of FBB-PET and plasma ratios. B) Shapiro-Wilk test for FBB-PET and plasma...

Additional file 4: of Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Milos Ikonomovic (3399359)
Chris Buckley (3399341)
Kerstin Heurling (3399347)
Paul Sherwin (3399338)
Paul Jones (1523707)
Michelle Zanette (3399344)
Chester Mathis (3399368)
William Klunk (3399353)
Aruna Chakrabarty (3399356)
James Ironside (3399371)
Azzam Ismail (3399350)
Colin Smith (6343)
Dietmar Thal (3399362)
Thomas Beach (559420)
Gill Farrar (3399365)
Adrian Smith (2385022)

December 2016

ROC Analysis: Dichotomised pathology vs continuous SUVR. Comparison of 5 histopathological criteria ...

Additional file 3: of 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

Richard Tsai (2839040)
Alexandre Bejanin (6286391)
Orit Lesman-Segev (6286394)
Renaud LaJoie (6286397)
Adrienne Visani (6286400)
Viktoriya Bourakova (6286403)
James O’Neil (6286406)
Mustafa Janabi (6286409)
Suzanne Baker (6286412)
Suzee Lee (6286415)
David Perry (358135)
Lynn Bajorek (6286418)
Anna Karydas (531627)
Salvatore Spina (6251273)
Lea Grinberg (3456281)
William Seeley (3456287)
Eliana Ramos (6286421)
Giovanni Coppola (46572)
Maria Gorno-Tempini (6286424)
Bruce Miller (695078)
Howard Rosen (6029381)
William Jagust (518155)
Adam Boxer (801729)
Gil Rabinovici (2839046)

February 2019

Figure S3. 18F-flortaucipir in FTD, NC and AD 18F-flortaucipir SUVR in temporal and precentral gyrus...

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Abstract

Extracted data

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Abstract

Extracted data

Related items

Related items

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Abstract

Extracted data

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Abstract

Extracted data

Related items

Related items

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)

Additional file 4: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)